Navigation Links
Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
Date:8/6/2009

s its programs under development; and the expected receipt of clinical trial data from Genentech in the second half of 2010 and the expected shareholder and corporate benefits of any advancement of clinical trials of GDC-0449;. Forward-looking statements used in this press release may contain the words "believes", "expects", "anticipates", "plans", "seeks", "estimates", "will", "may" or similar expressions. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties, assumptions and other important factors that may cause the actual results to be materially different from those indicated by such forward-looking statements including, among other things:

    - Curis may experience adverse results, delays and/or failures
      in its internal drug development programs, including with respect to
      its phase I clinical trial of CUDC-101, and with respect to its ongoing
      preclinical studies of its other targeted cancer programs.
    - Genentech and Debiopharm may experience adverse results, delays
      and/or failures in their strategic alliance transactions with Curis.
      For example, Genentech may not be able to replicate in later trials any
      favourable outcomes from earlier trials of GDC-0449, and Debiopharm may
      not be able to successfully advance CUDC-305 into clinical trials as
      planned.
    - Curis may experience difficulties or delays in obtaining or
      maintaining required regulatory approvals for products under
      development both internally and through its collaborations.
    - Curis may not be able to obtain or maintain the intellectual
      property protection necessary for the development and commercialization
      of drug candidates based on its technologies.
    - Curis may not be able to obtain the substantial additional
      funding required to conduct research and development of its drug
      candidates.
    - Curis may experien
'/>"/>
SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
2. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
3. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
4. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
5. Japanese Cancer Association and Debiopharm Honour Japanese Research
6. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
7. Debiopharm and EPFL Establish an Oncology Chair
8. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
9. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
10. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
11. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... NEW YORK , Sept. 1, 2014 /PRNewswire/ ... report is available in its catalogue: ... Opportunities, 2019 http://www.reportlinker.com/p02350445/India-Solid-Waste-Management-Vehicles-Market-Forecast-and-Opportunities-2019.html ... municipal corporations are the main governing bodies responsible ... management in cities. On an average, around 135,000 ...
(Date:8/31/2014)... September 01, 2014 Available spectra ... needs for research and cultivation of a wide ... Valoya’s proprietary LEDs with proven patented and pending ... uncompromised light uniformity in critical applications in contrast ... LEDs. , “Our customers have a large variety ...
(Date:8/29/2014)... 2014  Pfenex Inc. (NYSE MKT: PFNX), a ... high-value and difficult to manufacture proteins including biosimilar ... financial results for the second quarter ended June ... of our initial public offering, we have the ... candidates, derived from our proprietary protein expression platform," ...
(Date:8/29/2014)... Pittsburgh, PA (PRWEB) August 29, 2014 ... Chairman, Hub MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, ... JASIS on September 5, 2014. JASIS , Asia’s ... September 3-5, 2014, in Makuhari Messe, Japan. , ... New Tools for Bioanalysis from Single Molecules to Single ...
Breaking Biology Technology:India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 4India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 5India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 6India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 7India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 8Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2
... 63 unique dust particles from their laboratory and that,s ... new kind of sensor when dust got stuck inside it, ... single dust particles. In a recent issue of The ... the discovery could aid the study respiratory diseases caused by ...
... 2011 Professor Ian Phillips of Keck Graduate Institute (KGI) ... patent for a novel procedure that involves stem cells in ... covers a two-step process developed by Phillips and Yao Liang ... of pure stem cells for transplantation into the heart or ...
... Oct. 5, 2011 A recent survey of California,s ... great potential for job growth in the state. ... percent in the past five years, according to a ... industry associations in the state, and Radford, a compensation ...
Cached Biology Technology:1 room -- 63 different dust particles? Researchers aim to build dust library 21 room -- 63 different dust particles? Researchers aim to build dust library 3KGI Professor Awarded Patent for Stem-Cell Therapy Aiding Heart-attack Patients 2California's Industrial Biotechnology Workforce: Creating Jobs and Leading Innovation 2California's Industrial Biotechnology Workforce: Creating Jobs and Leading Innovation 3
(Date:8/31/2014)... test provides a fast and accurate tool to ... shows. The newly developed test (TAM-TB assay) is ... tuberculosis in children. The test features excellent specificity, ... with speed of a blood test. The promising ... of tuberculosis in children, particularly in tuberculosis-endemic regions. ...
(Date:8/31/2014)... Nature Climate Change , suggests that if current trends ... the global targets for total greenhouse gas (GHG) emissions in ... think carefully about the food we choose and its environmental ... just one of a number of actions that need to ... is enough food for all. , As populations rise ...
(Date:8/29/2014)... recently, little has been known about what genetic changes ... of scientists, one of whom is a University of ... that genes controlling the development of the brain and ... The study was published Aug. 28 in Science ... is online at http://www.sciencemag.org/ ., The domestication of ...
Breaking Biology News(10 mins):New tuberculosis blood test in children is reliable and highly specific 2Changing global diets is vital to reducing climate change 2Changing global diets is vital to reducing climate change 3Changing global diets is vital to reducing climate change 4New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3
... of novel marine microbes could lead to more efficient ... such as epilepsy, diabetes, flu and other viruses, as ... as agrochemicals. Researchers at Heriot-Watt University and Plymouth ... Ingenza Ltd are searching for new enzymes for use ...
... associated diseases cost pig producers around the world hundreds ... Kansas State University virologists Dick Hesse and Bob Rowland ... such complex diseases. "Circovirus and its associated diseases ... porcine reproductive and respiratory syndrome and circovirus are a ...
... Banks National Marine Sanctuary is among the healthiest coral ... Mexico, according to a new NOAA report. The ... Benthic Habitats within the Flower Garden Banks National Marine ... within the sanctuary based on data collected in 2006 ...
Cached Biology News:Marine microbes creating green waves in industry 2Marine microbes creating green waves in industry 3K-State lab gives researchers the tools to study porcine circovirus associated diseases 2NOAA report finds flower garden banks sanctuary reefs among healthiest in Gulf 2
Homo sapiens similar to Cytosolic acyl coenzyme A thioester hydrolase Antigen: Peptide...
96 Well Base Plate...
... Inhibitor is a potent noncompetitive ... as RNase A. Like other ... Inhibitor is an acidic protein ... kDa. RNaseOUT inhibits RNase A ...
... and Recombinant RNasin Ribonuclease Inhibitors have broad ... of eukaryotic RNases of the neutral type ... effect by noncovalently binding to RNases in ... the binding of RNasin Ribonuclease Inhibitor to ...
Biology Products: